Dr. Allen Davidoff, PhD, CEO of XORTX Therapeutics, a clinical-stage biotechnology company developing promising therapeutics for progressive kidney disease, discusses the company’s lead assets that are designed to reduce uric acid to alleviate genetic autosomal dominant polycystic kidney disease (ADPKD) and COVID-19-related kidney injury. The current approved treatment for ADPKD can cause liver failure among other severe symptoms.

Dr. Allen Davidoff (15 years drug development experience) is the founder and CEO of XORTX. Allen has a broad range of clinical and regulatory experience and senior management experience in pharmaceutical R&D including two investigational new drug (“IND”) applications or supplemental IND’s, two phase I studies (four of which were multi-country), seven phase II studies, and one NDA. Prior to forming XORTX, Allen was the Chief Scientific Officer, VP Product Development and co-founder of Stem Cell Therapeutics Corp. (seven years) ( Trillium TRIL:NASDAQ) and Senior Scientist and Head of Pharmacology at Cardiome Pharma Corp.

Liked it? Take a second to support healthprofessionalradio on Patreon!